Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.
P22-03
Phase 1 other active
Quick answer
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects. for Eosinophilic esophagitis is a Phase 1 program (other) at Bioprojet Pharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bioprojet Pharma
- Indication
- Eosinophilic esophagitis
- Phase
- Phase 1
- Modality
- other
- Status
- active